Biocompatibles puts shareholder issues behind it as it embarks on operational future in interventional radiology
This article was originally published in Clinica
Biocompatibles International CEO Crispin Simon has only one regret about this year's disposal of the cardiovascular stent business to Abbott, he told Clinica
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.